IOL Chem and Pharma Q1 FY27 earnings call

Where management's figures differ from the filing

• EBITDA: said INR111 cr, margin 14.6% (growth 60.7% YoY); filed ₹103.49 cr ex-other income, margin 13.7% (+66.5%). Mgmt EBITDA of ₹111 cr includes other income (₹8.18 cr per filed); mgmt margin 14.6% uses ₹756 cr revenue. Gap ~7.3% reflects inclusion of other income, not a re-statement of operating performance.

What moved the numbers, as management explained it

• Higher capacity utilization: most API assets at 80-95%, paracetamol at ~55% of expanded capacity; drove operating leverage on revenue growth of 37%.
• Improved product mix: non-ibu share rose to 43% of pharma from 36%; non-ibu revenue grew 67% YoY vs lower single-digit ibuprofen growth.
• Stronger export realizations (esp. non-ibu) and export share rising to 28.5% from 24.4% supported EBITDA margin expansion to 14.6%.
• Operational efficiencies and ability to pass on higher input costs (ethyl acetate, acetic anhydride) to customers supported margin expansion.
• Management explicitly denied material one-time inventory gain in Q1 (only minor 10-15 day benefit in late Q4 FY26); PAT growth was operational, not a base effect. (one-off)

The numbers management led with

• Non-ibuprofen share of pharma revenue: 43% in Q1 FY27 vs 36% in Q1 FY26; revenue +67% YoY
• Annual capex run-rate: ~INR200 cr/year with 60% for expansion/new products and 40% for infrastructure/efficiency
• Triacetin revenue potential: ~INR120 crores per year at 6,000 MTPA capacity (production started May 2026)
• FY27 revenue growth guidance: 15-20% for FY27

Guidance on this call

What changed since the Fri 22 May 2026 call

Guided on earlier calls, and what was filed

Filed figures are summed from the company's own quarterly results for the whole period (EBITDA excludes other income); where one sits against what was guided is arithmetic, not a judgement.

By business

Balance sheet, capex and funding

• Annual capex plan ~₹200 cr/year; 60% directed to expansion/new products and 40% to infrastructure/efficiency improvements.
• Historical capex range ₹100-200 cr/year over last 4-5 years; planned run-rate of ~₹200 cr/year for FY27-FY28.
• Triacetin plant (6,000 MTPA) commissioned; production started post-May 2026.

The industry, as management sees it

Management sees a healthy demand environment in both pharma and chemical segments with improved capacity utilization supporting margin expansion, despite continued geopolitical uncertainties, supply chain challenges and inflationary pressure on select raw materials. Regulatory approvals across multiple jurisdictions (US FDA, NMPA China) are opening incremental export opportunities for the diversified API platform.

Risks management named

• Continued geopolitical uncertainties, supply chain challenges and inflationary pressure on select raw materials
• Sequential gross margin compression due to lag in passing through higher input costs to contracted customers
• Quarter-to-quarter variability in export contribution driven by customer-level agreement dispatch patterns
• Dependence on Chinese sourcing of DCDA raw material for metformin (geographically concentrated)

Not answered directly

• Pharma volume vs price growth split (Vignesh)
• R&D pipeline specific product opportunities (Santosh of LGT Capital)
• Backward integration specific intermediates (Nimish Verma)
• CMO opportunity specifics (Sheikh Mohammed)
• Competitor comparison with SMS Pharma (Sheikh Mohammed)
• Triacetin vs ethyl acetate EBITDA margin comparison (Abhishek Kamdar)

Asked for a number, answered without one

• Pharma growth volume vs realization split: Majority from volume and capacity utilization; mgmt declined detailed split and said they do not share that level of detail on calls.
• One-time inventory gain from pricing surge: Mgmt denied material inventory gain in Q1 (only minor 10-15 day benefit in late Q4 FY26); attributed performance to capacity utilization, mix, operational efficiency, and export realizations.
• Triacetin vs Ethyl Acetate EBITDA margins: Mgmt declined, saying product usage is different and margins are not disclosed at product level.

Every question, with its answer

1. 1. Paracetamol outlook

   Abu Rafe, Wealth Catalyst4:17

   Question. Given paracetamol has seen weak demand over the past few years, what is the current outlook for paracetamol?

   Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. Paracetamol capacity was tripled from 3,600 MTPA to 10,800 MTPA last year. Currently operating at ~55% of enhanced capacity, expected to reach ~70% by end of FY27. Paracetamol is contributing significantly to the non-ibu portfolio and IOL is gaining traction both domestically and in exports.

2. 2. Chemical pricing environment

   Abu Rafe, Wealth Catalyst4:17

   Question. Given the sharp rise in ethyl acetate and acetic anhydride prices following the U.S.-Iran war, what is the current pricing environment for both products?

   Answer, Rakesh Mahajan, Finance Advisor and Strategic Head. Due to the war, prices increased substantially in March but have since stabilized. Prices are not on an upward trend over the past month. Management expects the delta between raw material and ethyl acetate prices to remain constant in upcoming quarters.

3. 3. Export mix trajectory

   Pahel Sharma, DD Capital5:23

   Question. Export contribution rose to 28.5% from 24.4% YoY — do you see this moving toward 30%+ in the near term, or maintain a more balanced domestic-export mix?

   Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. Targeting 25-30% range of export revenues for the year and hopeful of achieving it.

4. 4. EBITDA margin drivers

   Pahel Sharma, DD Capital5:23

   Question. Q1 EBITDA margin at 14.6% is ahead of the FY27 guidance range of 14-15%. What factors could sustain margin above the range or lead to moderation?

   Answer, Pardeep Kumar Khanna, Chief Financial Officer. Key drivers for the EBITDA margin lift: higher capacity utilization, better product mix, operational efficiencies and stronger non-ibu segment API demand. Also some improvement in finished product prices contributed.

5. 5. Pharma growth volume vs price

   Vignesh, Sequent Scientific Limited6:20

   Question. Pharma revenue grew ~42% YoY in Q1 FY27. What is the split between volume growth and realization growth?

   Answer, Rakesh Mahajan, Finance Advisor and Strategic Head. Exact numbers not shared, but the majority of growth came from increased volumes of pharma products rather than finished product prices. Capacity utilization of API products including non-ibu segments has increased.

   Not answered directly.

6. 6. Regulated market mix

   Vignesh, Sequent Scientific Limited6:20

   Question. Has the mix toward regulated markets increased this quarter, aiding the higher EBITDA margin?

   Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. For other API products, yes.

7. 7. Non-ibuprofen growth and regulated mix

   Surabhi Sutaria, NV Alpha17:16

   Question. Non-Ibuprofen has crossed an INR200 cr quarterly run rate. What is driving that growth? How much of the INR200 cr is regulated market, and how much more can be supplied to regulated markets?

   Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. Around 21-20% of non-ibu comes from the export market, including regulated and non-regulated; majority is from regulated markets. Achieved ~43% non-ibu of overall pharma this year and very close to the 50/50 non-ibu vs ibu target discussed over recent quarters.

   Partly answered.

8. 8. Non-ibuprofen product mix

   Surabhi Sutaria, NV Alpha17:16

   Question. Of the non-ibuprofen APIs, which is the biggest contributor — clopidogrel or pantoprazole?

   Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. Paracetamol, clopidogrel, pantoprazole, metformin, fenofibrate and levetiracetam are key growth drivers and key products in this segment.

   Partly answered.

9. 9. Capex composition

   Jainam Ghelani, Svan Investments19:34

   Question. Capex guidance is INR200-250 cr — how much is maintenance capex and how much is growth capex? Is it for the greenfield site with EC approval or other projects?

   Answer, Pardeep Kumar Khanna, Chief Financial Officer. Annual capex of approximately INR200 crores with a long-term view to support sustainable growth. 60% is directed to expansion and new product; remaining 40% to infrastructure, efficiency improvements and cost reduction. Capex has been INR100-200 cr annually for the past 4-5 years.

10. 10. Inventory gain attribution

    Jainam Ghelani, Svan Investments20:37

    Question. How much of this quarter's profitability should be attributed to one-time inventory gain from the pricing surge tied to the war?

    Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. Not correct to attribute this quarter's profit to inventory gain — there was a marginal inventory gain in the last 10-15 days of the prior quarter but not this quarter. Performance is driven by higher capacity utilization, better product mix, operational efficiency, better non-ibu performance and increased export realizations in non-ibu.

11. 11. Non-ibuprofen impact on pharma margins

    Santosh, LGT Capital22:26

    Question. Non-ibuprofen share rose from 36% to 43% of pharma revenue. At what point does this portfolio become large enough to materially change the overall pharma margin profile?

    Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. Expecting non-ibu to achieve ~50% of pharma in the near term, with the 50% further divided between domestic and exports. Achieving this milestone, combined with rising export realizations, should change the overall contribution to the bottom line.

12. 12. R&D pipeline

    Santosh, LGT Capital22:26

    Question. With INR26 cr spent on R&D in FY26, what are the key commercial opportunities emerging from the R&D pipeline and what contribution can we expect over the medium term?

    Answer, Kushal Kumar Rana, Director Works. R&D spend is regular and not one-off, not allocated to a specific product development. Significant funds have been allocated to high-end analytical equipment — XRD, LCMS, GCMS machines — to analyze impurity profile at stringent levels.

    Not answered directly.

13. 13. EBITDA outperformance drivers

    Soumya, Nirva Securities24:43

    Question. Q1 revenue grew 37% YoY while EBITDA grew 60.7%. How much of the EBITDA outperformance was driven by operating leverage vs improvement in product mix?

    Answer, Rakesh Mahajan, Finance Advisor and Strategic Head. EBITDA margin increase is primarily due to operational efficiencies of existing products with increased capacity utilization. No major product mix change except more penetration in export market. The outperformance is mostly internal efficiencies, not external factors.

14. 14. PAT growth drivers

    Soumya, Nirva Securities24:43

    Question. PAT grew 89.9% YoY. Apart from operating performance, were there any one-offs or below-EBITDA factors that contributed to the sharp PAT growth?

    Answer, Rakesh Mahajan, Finance Advisor and Strategic Head. Nothing extraordinary — a routine financial outcome driven by internal efficiencies.

15. 15. Pharma growth broad-based vs concentrated

    Soumya, Nirva Securities26:36

    Question. Pharma revenue grew 43% YoY. Was the growth broad-based across the portfolio or concentrated in a few key products?

    Answer, Kushal Kumar Rana, Director Works. Across the portfolio — all products have achieved maximum efficiencies with respect to utilization.

16. 16. Non-ibuprofen FY29 target

    Soumya, Nirva Securities27:08

    Question. If the diversification strategy plays out as planned, what is a reasonable non-ibuprofen target for pharma revenue by FY29, and would the mix shift structurally lift consolidated margins?

    Answer, Rakesh Mahajan, Finance Advisor and Strategic Head. For FY29 — only after three to four years — non-ibu segment is expected to contribute around 50-55% of the API segment with margins equivalent to other (non-ibuprofen) API margins.

17. 17. Demand revival and sustainability

    Maulik Varia, 360 ONE Mutual Fund28:19

    Question. Strong top-line growth across products. Why was growth muted in the last few quarters, what led to the revival, and how long will this strong demand sustain — 8 to 12 quarters? Any quantitative direction on demand?

    Answer, Pardeep Kumar Khanna, Chief Financial Officer. Growth came from higher volumes plus better pricing of established products and growth in new products. Despite input price increases, the company passed costs through due to healthy demand in both domestic and export markets. Expect ~20% revenue growth and 14-15% EBITDA. Reasonable visibility into order book for coming quarter — growth sustainable for the whole year.

18. 18. FY28 guidance

    Maulik Varia, 360 ONE Mutual Fund29:03

    Question. Any guidance on FY28 — similar 15-20% top-line and similar EBITDA margin run-rate?

    Answer, Pardeep Kumar Khanna, Chief Financial Officer. Plan to grow 15-20% in top line and EBITDA at 15-17% in FY28 approximately.

    Partly answered.

19. 19. Sequential gross margin

    Maulik Varia, 360 ONE Mutual Fund31:09

    Question. Sequentially gross margin declined. Is it because last quarter had some inventory gains, and this quarter had higher input costs with gross margins relatively lower sequentially?

    Answer, Rakesh Mahajan, Finance Advisor and Strategic Head. Yes — in March quarter there was an inventory valuation benefit for a few days. This quarter both input and finished prices increased, but margin was impacted by variation in passing through increased cost to contracted customers. These differences are now exhausted; no major variation expected going forward.

20. 20. Other expenses composition

    Maulik Varia, 360 ONE Mutual Fund32:45

    Question. Other expenses also increased QoQ — what is the major contributor?

    Answer, Pardeep Kumar Khanna, Chief Financial Officer. Major costs in other expenses are energy and logistics. Power cost and logistic cost increased during the quarter, but the company passed on the major part to customers — no material impact on the business.

21. 21. Non-ibuprofen key products

    Maulik Varia, 360 ONE Mutual Fund45:54

    Question. Going ahead, for FY27 and beyond, which products will be the key drivers of the non-ibuprofen outperformance — or will it be the entire portfolio?

    Answer, Pardeep Kumar Khanna, Chief Financial Officer. Paracetamol turnover contributed mainly to the increase; clopidogrel and pantoprazole also contributed. Overall, all products contributed. Going ahead, broad-based growth across the non-ibu portfolio is expected.

22. 22. Regulated market filings

    Maulik Varia, 360 ONE Mutual Fund46:11

    Question. On regulated market exports — any new products filed or awaiting approval?

    Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. All products have CEP approval; in addition, five products have US FDA approval and another two-three are lined up via formulators' ANDAs (once approved, IOL's APIs also get approved). NMPA China recently approved clopidogrel; ibuprofen also approved in China previously.

23. 23. Ibuprofen share evolution

    Nimish Verma, AAS Capital46:40

    Question. As the broader API portfolio scales, how do you see ibuprofen's share of total revenue evolving over the next three years?

    Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. Ibuprofen is one of IOL's best products but the company is now a diversified API player. The same leadership model established in ibuprofen will be replicated for other products as they reach scalability. Growth will be broad-based across the product portfolio with better product mix.

24. 24. Backward integration opportunities

    Nimish Verma, AAS Capital46:40

    Question. Are there specific intermediates or KSMs being evaluated for backward integration that could meaningfully improve product economics?

    Answer, Kushal Kumar Rana, Director Works. Working on different R&D streams but can share more only when proof-of-concept is ready after R&D development.

    Not answered directly.

25. 25. Greenfield 101-acre land parcel

    Nimish Verma, AAS Capital46:40

    Question. With the 101-acre land parcel available for expansion, should we expect the first major project to be commissioned within the current capex cycle, or is it an FY28-29 growth platform?

    Answer, Kushal Kumar Rana, Director Works. Statutory permissions are underway; parallel R&D work on different product mix is ongoing. Once proof-of-concept is ready, work will start and product will come from that site — but probably not in this FY.

26. 26. Chemical segment outlook

    Sheikh Mohammed, Individual Investor47:46

    Question. Will the chemical business continue to perform at the same level, or have we seen peak EBITDA margins for the chemical segment?

    Answer, Pardeep Kumar Khanna, Chief Financial Officer. EBITDA margin of the chemical segment has been on an upward trend this quarter. Capacities of ethyl acetate and acetic anhydride were increased and the company has done better. Increased exports in chemicals also contributed. Expect this performance to continue.

27. 27. CMO opportunity

    Sheikh Mohammed, Individual Investor47:46

    Question. Last conference call, you mentioned the CMO space. What opportunity can IOL fulfill in CMO?

    Answer, Kushal Kumar Rana, Director Works. Working on that segment; once proof-of-concept is ready, will share details.

    Not answered directly.

28. 28. Guidance upgrade potential

    Sheikh Mohammed, Individual Investor47:46

    Question. With prior full-year top-line guidance of INR2,600-2,700 cr, do you think Q1 performance allows you to outperform that guidance on top line and bottom line?

    Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. Previous guidance was for the full year; it will remain on the same line. However, on current scenario the company may cross that number, but does not want to upgrade the guidance.

29. 29. Export guidance conservatism

    Sheikh Mohammed, Individual Investor47:46

    Question. Exports are already at 28.5% — is management being defensive with the 25-30% guidance range?

    Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. Achieved 28.5% and expecting ~30%. If the company says around 30%, it can be 28% or 35% — this is the mean. Preferring to be accurate rather than over-promising; hopeful of achieving it, may cross it.

30. 30. Chemical regulatory approvals

    Sheikh Mohammed, Individual Investor47:46

    Question. Are there further regulatory approvals being planned for the chemical segment or for other products in chemicals?

    Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. Two main products — ethyl acetate (100% merchant sale) and acetic anhydride — are approved with recertification in place. Triacetin was introduced last quarter and regulatory approvals are expected to come in two-three quarters.

31. 31. Competitor comparison

    Sheikh Mohammed, Individual Investor49:24

    Question. SMS Pharma's revenue and profit were both hit this quarter. Have we beaten them in ibuprofen manufacturing technology?

    Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. Tricky question; doesn't know about others and doesn't want to comment. Confident about IOL's strategy, manufacturing capabilities and operational efficiency.

    Not answered directly.

32. 32. Triacetin capacity utilization

    Abhishek Kamdar, Value Plus Advisors49:43

    Question. On Triacetin, the new facility that commissioned — what is the capacity utilization achieved in Q1?

    Answer, Kushal Kumar Rana, Director Works. Triacetin plant started production after May 2026 — only about one month of production in Q1. Capacity will increase slowly as market penetration progresses.

33. 33. Triacetin revenue potential

    Abhishek Kamdar, Value Plus Advisors49:43

    Question. At steady state, what is the revenue potential of the 6,000 MTPA Triacetin facility?

    Answer, Pardeep Kumar Khanna, Chief Financial Officer. Around INR120 crores per year at full capacity.

34. 34. Triacetin inputs

    Abhishek Kamdar, Value Plus Advisors49:43

    Question. Are Triacetin inputs acetic anhydride, and what percentage of acetic anhydride would be captive consumption?

    Answer, Kushal Kumar Rana, Director Works. Inputs are acetic acid and glycerol — acetic anhydride is not used in this product.

35. 35. Triacetin vs ethyl acetate margin

    Abhishek Kamdar, Value Plus Advisors49:43

    Question. How does Triacetin EBITDA margin compare with ethyl acetate?

    Answer, Kushal Kumar Rana, Director Works. Cannot be compared on a product basis — usage is totally different for both products.

    Not answered directly.

36. 36. Backward integration gaps

    Santosh Shetty, LSG Capital50:30

    Question. Backward integration has been an important strategy. Are there significant raw materials or intermediates where IOL is still dependent on external sourcing and could integrate further?

    Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. Metformin is not backward integrated; IOL is dependent on DCDA from China for metformin. Most companies also depend on China for DCDA because it is geographically available in that region.

37. 37. Export mix benefit drivers

    Santosh Shetty, LSG Capital50:30

    Question. Export contribution has moved to 28.5%. Is the higher export mix resulting in better product/customer mix, or is the benefit primarily from higher volumes?

    Answer, Abhay Raj Singh, Senior Vice President & Company Secretary. It is a mix of everything — better product mix, operational efficiency, better realization and customer reach. No specific reason dominates.

    Partly answered.

Topic by topic, in the order it was spoken

In their words